FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1571178250> ?p ?o ?g. }

• W1571178250 endingPage "1115" @default.
• W1571178250 startingPage "1108" @default.
• W1571178250 abstract "Combinations of beta-lactams plus aminoglycosides have been standard therapy for suspected infections in granulocytopenic cancer patients, especially those with profound long-lasting granulocytopenia. With the advent of new broad-spectrum bactericidal antibiotics such as extended-spectrum cephalosporins or carbapenems, the need to combine beta-lactams with aminoglycosides became more controversial. The objective of this prospective randomized multicenter study was to compare the efficacy, safety, and tolerance of meropenem monotherapy with those of the combination of ceftazidime plus amikacin for the empirical treatment of fever in granulocytopenic cancer patients. Of 1,034 randomized patients, 958 were assessable in the intent-to-treat analysis for response to antibacterial therapy, including 483 in the meropenem group and 475 in the ceftazidime-plus-amikacin group. The median durations of neutropenia were 16 and 17 days, respectively. A successful outcome was reported in 270 of 483 (56%) patients treated with monotherapy compared with 245 of 475 (52%) patients treated with the combination group (P = 0.20). The success rates in the monotherapy group and the combination group were similar by type of infection (single gram-negative bacteremia, single gram-positive bacteremia, clinically documented infection, and possible infection). The occurrence of further infections assessed in patients for whom the allocated regimen was not modified did not differ between the two groups (12% in both groups). Mortality due to the presenting infection or further infection was relatively low (8 patients treated with the monotherapy compared with 13 patients treated with the combination). A total of 1,027 patients were evaluable for adverse events; the proportion of those who developed adverse effects was similar between the two groups (29% in both groups), and only 19 (4%) patients in the monotherapy group and 31 (6%) in the combination group experienced an adverse event related or probably related to the study drug. Allergic reactions were the only reason for stopping the protocol antibiotic(s) (3 and 5 patients, respectively). This study confirms that monotherapy with meropenem is as effective as the combination of ceftazidime plus amikacin for the empiric treatment of fever in persistently granulocytopenic cancer patients, and both regimens were well tolerated." @default.
• W1571178250 created "2016-06-24" @default.
• W1571178250 creator A5009015325 @default.
• W1571178250 creator A5020303625 @default.
• W1571178250 creator A5028099562 @default.
• W1571178250 creator A5039916761 @default.
• W1571178250 creator A5057557133 @default.
• W1571178250 creator A5058024552 @default.
• W1571178250 creator A5061843949 @default.
• W1571178250 creator A5063119815 @default.
• W1571178250 creator A5069291690 @default.
• W1571178250 creator A5072001348 @default.
• W1571178250 creator A5073851794 @default.
• W1571178250 creator A5081801675 @default.
• W1571178250 creator A5082455844 @default.
• W1571178250 creator A5082745903 @default.
• W1571178250 creator A5083097116 @default.
• W1571178250 creator A5088624316 @default.
• W1571178250 date "1996-05-01" @default.
• W1571178250 modified "2023-09-27" @default.
• W1571178250 title "Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program" @default.
• W1571178250 cites W1955222196 @default.
• W1571178250 cites W1968108660 @default.
• W1571178250 cites W1981612169 @default.
• W1571178250 cites W1984864482 @default.
• W1571178250 cites W1997947730 @default.
• W1571178250 cites W2015842254 @default.
• W1571178250 cites W2029987806 @default.
• W1571178250 cites W2043115243 @default.
• W1571178250 cites W2043977100 @default.
• W1571178250 cites W2054962356 @default.
• W1571178250 cites W2057760541 @default.
• W1571178250 cites W2085054454 @default.
• W1571178250 cites W2086546987 @default.
• W1571178250 cites W2091354107 @default.
• W1571178250 cites W2101760119 @default.
• W1571178250 cites W2102616245 @default.
• W1571178250 cites W2118765654 @default.
• W1571178250 cites W2126565263 @default.
• W1571178250 cites W2133525603 @default.
• W1571178250 cites W2331910443 @default.
• W1571178250 cites W2341550006 @default.
• W1571178250 cites W3022798003 @default.
• W1571178250 cites W2278124212 @default.
• W1571178250 doi "https://doi.org/10.1128/aac.40.5.1108" @default.
• W1571178250 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/163274" @default.
• W1571178250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8723449" @default.
• W1571178250 hasPublicationYear "1996" @default.
• W1571178250 type Work @default.
• W1571178250 sameAs 1571178250 @default.
• W1571178250 citedByCount "250" @default.
• W1571178250 countsByYear W15711782502012 @default.
• W1571178250 countsByYear W15711782502013 @default.
• W1571178250 countsByYear W15711782502014 @default.
• W1571178250 countsByYear W15711782502015 @default.
• W1571178250 countsByYear W15711782502016 @default.
• W1571178250 countsByYear W15711782502017 @default.
• W1571178250 countsByYear W15711782502018 @default.
• W1571178250 countsByYear W15711782502019 @default.
• W1571178250 countsByYear W15711782502021 @default.
• W1571178250 countsByYear W15711782502022 @default.
• W1571178250 countsByYear W15711782502023 @default.
• W1571178250 crossrefType "journal-article" @default.
• W1571178250 hasAuthorship W1571178250A5009015325 @default.
• W1571178250 hasAuthorship W1571178250A5020303625 @default.
• W1571178250 hasAuthorship W1571178250A5028099562 @default.
• W1571178250 hasAuthorship W1571178250A5039916761 @default.
• W1571178250 hasAuthorship W1571178250A5057557133 @default.
• W1571178250 hasAuthorship W1571178250A5058024552 @default.
• W1571178250 hasAuthorship W1571178250A5061843949 @default.
• W1571178250 hasAuthorship W1571178250A5063119815 @default.
• W1571178250 hasAuthorship W1571178250A5069291690 @default.
• W1571178250 hasAuthorship W1571178250A5072001348 @default.
• W1571178250 hasAuthorship W1571178250A5073851794 @default.
• W1571178250 hasAuthorship W1571178250A5081801675 @default.
• W1571178250 hasAuthorship W1571178250A5082455844 @default.
• W1571178250 hasAuthorship W1571178250A5082745903 @default.
• W1571178250 hasAuthorship W1571178250A5083097116 @default.
• W1571178250 hasAuthorship W1571178250A5088624316 @default.
• W1571178250 hasBestOaLocation W15711782501 @default.
• W1571178250 hasConcept C126322002 @default.
• W1571178250 hasConcept C141071460 @default.
• W1571178250 hasConcept C142724271 @default.
• W1571178250 hasConcept C204787440 @default.
• W1571178250 hasConcept C2776694085 @default.
• W1571178250 hasConcept C2776968632 @default.
• W1571178250 hasConcept C2776999253 @default.
• W1571178250 hasConcept C2777063308 @default.
• W1571178250 hasConcept C2777427914 @default.
• W1571178250 hasConcept C2777637488 @default.
• W1571178250 hasConcept C2779181126 @default.
• W1571178250 hasConcept C2779375183 @default.
• W1571178250 hasConcept C2779443120 @default.
• W1571178250 hasConcept C2781413609 @default.
• W1571178250 hasConcept C501593827 @default.
• W1571178250 hasConcept C523546767 @default.
• W1571178250 hasConcept C54355233 @default.
• W1571178250 hasConcept C71924100 @default.

• next